Effects of sulfated polysaccharides on tumour biology

West Indian Medical Journal

Volumn 55, Issue 4, 2006, Pages 270-273

  Wu, Xiong Zhi ^a   Chen, D ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; GROWTH FACTOR; HEPARAN SULFATE; HEPARANASE; P1 88; POLYSACCHARIDE SULFATE; PROTEOHEPARAN SULFATE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR IMMUNITY; DRUG PROTEIN BINDING; ENZYME INHIBITION; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; NONHUMAN; TUMOR CELL;

EID: 34547686429     PISSN: 00433144     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0043-31442006000400009     Document Type: Article

References (43)

1. Smorenburg SM, Hutten B, Prins M. Should patients with venous thromboembolism and cancer be treated differently? Haemostasis 1999; 29: 91-7.
2. Green D, Hull RD, Brant R, Pineo CF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992; 339:1476.
3. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-9.
4. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001; 53: 93-106.
5. Bitan M, Mohsen M, Levi E, Wygoda MR, Miao HQ, Lider O et al. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin. Isr J Med Sci 1995; 31: 106-18.
6. Bertolesi GE, Lauria de Cidre L, Eijan AM. Growth inhibition in vitro of murine mammary adenocarcinoma cells by heparin and chemically modified heparins. Tumour Biol 1994; 15: 275-83.
7. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130-5.
8. Williams DL, Pretus HA, McNamee RB, Jones EL, Ensley HE, Browder IW et al. Development, physicochemical characterization and preclinical efficacy evaluation of a water soluble glucan sulfate derived from Saccharomyces cerevisiae. Immunopharmacol 1991; 22:139-55.
9. Miao HQ, Elkin M, Aingorn E, Ishai-Michaeli R, Stein CA, Vlodavsky I. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer 1999; 83: 424-31.
10. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999; 59: 3433-41.
11. Murata J, Saiki J, Makabe T, Tsuta Y, Tokura S, Azuma I. Inhibition of tumor-induced angiogenesis by sulfated chitin derivatives. Cancer Res 1991; 51: 22-6.
12. Jayson GC, Gallagher JT. Heparin oligosaccharides: Inhibitors of the biological activity of bFGF on Caco-2 cells. Br J Cancer 1997; 75: 9-16.
13. Pisano C, Aulicino C, Vesci L, Casu B, Naggi A, Torri G et al. Under-sulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology 2005; 15: 1C-6C.
14. Norrby K. Heparin and angiogenesis: A low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. Haemostasis 1993; 23: 141-9.
15. Norrby K, Ostergaard P. Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int J Microcirc Clin Exp 1996; 16: 8-15.
16. Norrby K, Ostergaard P. A 5.0-kD heparin fraction systemically suppresses VEGF165- mediated angiogenesis. Int J Microcirc Clin Exp 1997; 17: 314-21.
17. Lepri A, Benelli U, Bernardini N, Bianchi F, Lupetti M, Danesi R et al. Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization. J Ocul Pharmacol 1994; 10: 273-80.
18. Joyce JA, Freeman C, Meyer-Morse N, Parish CR, Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 2005; 24: 4037-51.
19. McCarthy JB, Skubitz AP, Qi Z, Yi XY, Mickelson DJ, Klein DJ et al. RGD-independent cell adhesion to the carboxy-terminal heparin-binding fragment of fibronectin involves heparin-dependent and - independent activities. J Cell Biol 1990; 110: 777-87.
20. Antachopoulos CT, Gagos S, Iliopoulos DC, Karayannacos PE, Tseleni-Balafouta S, Alevras P et al. Low-dose heparin treatment does not inhibit SW480 human colon cancer growth and metastasis in vivo. In Vivo 1996; 10: 527-31.
21. Zvibel I, Halay E, Reid LM. Heparin and hormonal regulation of mRNA synthesis and abundance of autocrine growth factors: relevance to clonal growth of tumors. Mol Cell Biol 1991; 11: 108-16.
22. Bertolesi GE, Lauria de Cidre L, Eijan AM. Growth inhibition in vitro of murine mammary adenocarcinoma cells by heparin and chemically modified heparins. Tumour Biol 1994; 15: 275-83.
23. Bourgougnon N, Roussakis C, Komprobst JM, Lahaye M. Effects in vitro of sulfated polysaccharide from Schizymenia dubyi (Rhodophyta, Gigartinales) on a non-small-cell bronchopulmonary carcinoma line (NSCLC-N6). Cancer Lett 1994; 85: 87-92.
24. Aisa Y, Miyakawa Y, Nakazato T, Shibata H, Saito K, Ikeda Y et al. Fucoidan induces apoptosis of human HS-sultan cells accompanied by activation of caspase-3 and down-regulation of ERK pathways. Am J Hematol 2005; 78: 7-14.
25. Jemth P, Kreuger J, Kusche-Gullberg M, Sturiale L, Gimenez-Gallego G, Lindahl U. Biosynthetic oligosaccharide libraries for identification of protein-binding heparan sulfate motifs. Exploring the structural diversity by screening for fibroblast growth factor (FGF)1 and FGF2 binding. J Biol Chem 2002; 277: 30567-73.
26. Moczar M, Caux F, Bailly M, Berthier O, Dore JF. Accumulation of heparan sulfate in the culture of human melanoma cells with different metastatic ability. Clin Exp Metastasis 1993; 11: 462-71.
27. Desnoyers L. Structural basis and therapeutic implication of the interaction of CCN proteins with glycoconjugates. Curr Pharm Des 2004; 10: 3913-28.
28. Riou D, Colliec-Jouault S, Pinczon du Sel D, Bosch S, Siavoshian S, Le Bert V et al. Antitumor and antiproliferative effects of a fucan extracted from ascophyllum nodosum against a non-small-cell bronchopulmonary carcinoma line. Anticancer Res 1996; 16: 1213-8.
29. Matsuda M, Yamori T, Naitoh M, Okutani K. Structural revision of sulfated polysaccharide B-1 isolated from a marine Pseudomonas species and its cytotoxic activity against human cancer cell lines. Mar Biotechnol (NY) 2003; 5: 13-9.
30. Berry D, Lynn DM, Sasisekharan R, Langer R. Poly (beta-amino ester)s promote cellular uptake of heparin and cancer cell death. Chem Biol 2004; 11: 487-98.
31. Salmivirta M, Safaiyan F, Prydz K, Andresen MS, Aryan M, Kolset SO. Differentiation-associated modulation of heparan sulfate structure and function in CaCo-2 colon carcinoma cells. Glycobiology 1998; 8: 1029-36.
32. Margolis RK, Salton SR, Margolis RU. Effects of nerve growth factor-induced differentiation on the heparan sulfate of PC12 pheochromocytoma cells and comparison with developing brain. Arch Biochem Biophys 1987; 257: 107-14.
33. Bourgougnon N, Roussakis C, Kornprobst JM, Lahaye M. Effects in vitro of sulfated polysaccharide from Schizymenia dubyi (Rhodophyta, Gigartinales) on a non-small-cell bronchopulmonary carcinoma line (NSCLC-N6). Cancer Lett 1994; 85: 87-92.
34. Gorelik E. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice. Cancer Res 1987; 47: 809-15.
35. Gorelik E, Bere WW, Herberman RB. Role of NK cells in the antimetastatic effect of anticoagulant drugs. Int J Cancer 1984; 33: 87-94.
36. Yim JH, Son E, Pyo S, Lee HK. Novel sulfated polysaccharide derived from red-tide microalga Gyrodinium impudicum strain KG03 with immunostimulating activity in vivo. Mar Biotechnol (NY) 2005; 7: 331-8.
37. Zhou G, Xin H, Sheng W, Sun Y, Li Z, Xu Z. In vivo growth-inhibition of S180 tumour by mixture of 5-Fu and low molecular lambda-carrageenan from Chondrus ocellatus. Pharmacol Res 2005; 51: 153-7.
38. O'Sullivan GM, Boswell CM, Halliday GM. Langerhans cell migration is modulated by N-sulfated glucosamine moieties in heparin. Exp Dermatol 2000; 9: 25-33.
39. Dziarski R. Synergistic enhancement of T-cell responses and interleukin-1 receptor expression by interleukin-1 and heparin or dextran sulfate. Cell Immunol 1992; 145: 100-10.
40. Dziarski R. Enhancement of mixed leukocyte reaction and cytotoxic antitumor responses by heparin. J Immunol 1989; 143: 356-65.
41. Miao B, Li J, Fu X, Ding J, Geng M. T-cell receptor (TCR)/CD3 is involved in sulfated polymannuroguluronate (SPMG)-induced T lymphocyte activation. Int Immunopharmacol 2005; 5: 1171-82.
42. Parish CR, McPhun V, Warren HS. Is a natural ligand of the T lymphocyte CD2 molecule a sulfated carbohydrate? J Immunol 1988; 141: 3498-504.
43. Miao B, Geng M, Li J, Li F, Chen H, Guan H et al. Sulfated polymannuroguluronate, a novel anti-acquired immune deficiency syndrome (AIDS) drug candidate, targeting CD4 in lymphocytes. Biochem Pharmacol 2004; 68: 641-9.